Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Interest Expenses (2022 - 2025)

Tarsus Pharmaceuticals has reported Interest Expenses over the past 4 years, most recently at $2.2 million for Q4 2025.

  • Quarterly results put Interest Expenses at $2.2 million for Q4 2025, down 4.24% from a year ago — trailing twelve months through Dec 2025 was $8.9 million (up 13.84% YoY), and the annual figure for FY2025 was $8.9 million, up 13.84%.
  • Interest Expenses for Q4 2025 was $2.2 million at Tarsus Pharmaceuticals, down from $2.3 million in the prior quarter.
  • Over the last five years, Interest Expenses for TARS hit a ceiling of $2.4 million in Q3 2024 and a floor of $316000.0 in Q1 2022.
  • Median Interest Expenses over the past 4 years was $986000.0 (2023), compared with a mean of $1.4 million.
  • Biggest five-year swings in Interest Expenses: skyrocketed 184.97% in 2024 and later dropped 7.24% in 2025.
  • Tarsus Pharmaceuticals' Interest Expenses stood at $692000.0 in 2022, then soared by 42.92% to $989000.0 in 2023, then skyrocketed by 133.77% to $2.3 million in 2024, then dropped by 4.24% to $2.2 million in 2025.
  • The last three reported values for Interest Expenses were $2.2 million (Q4 2025), $2.3 million (Q3 2025), and $2.2 million (Q2 2025) per Business Quant data.